[[(1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 21678144 |
| CHEMBL ID | 1088844 |
| CHEBI ID | 93748 |
| Synonym |
|---|
| HMS3269O11 |
| BRD-K99922388-001-01-2 |
| NCGC00186012-01 |
| bdbm50315563 |
| {[(1s,2s,5r)-5-methyl-2-(propan-2-yl)cyclohexyl](phenyl)phosphoryl}benzene |
| CHEMBL1088844 , |
| HMS3261N07 |
| dpo-1 |
| (+)-neomenthyl diphenylphosphine oxide |
| 43077-30-1 |
| LP00543 |
| CCG-221847 |
| NCGC00261228-01 |
| tox21_500543 |
| [1s-(1?,2?,5?)]-[5-methyl-2-(1-methylethyl)cyclohexyl]diphenylphosphine oxide |
| diphenyl phosphine oxide-1 |
| neomenthyldiphenylphosphine oxide |
| [(1s,2s,5r)-2-isopropyl-5-methylcyclohexyl](diphenyl)phosphine oxide |
| BPCNGVCAHAIZEE-COPCDDAFSA-N |
| AKOS024457152 |
| DTXSID10616838 |
| CHEBI:93748 |
| dpo-1, needles, >97% (nmr) |
| dpo1 |
| gtpl11207 |
| [[(1s,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene |
| Q27165442 |
| ((1s,2s,5r)-2-isopropyl-5-methylcyclohexyl)diphenylphosphine oxide |
| HMS3677F13 |
| HMS3413F13 |
| SDCCGSBI-0633727.P001 |
| NCGC00186012-04 |
| dpo 1 |
| [1s-(1alpha,2alpha,5beta)]-[5-methyl-2-(1-methylethyl)cyclohexyl]diphenylphosphine oxide |
| h9lqp293gk , |
| phosphine oxide, (5-methyl-2-(1-methylethyl)cyclohexyl)diphenyl-, (1s-(1alpha,2alpha,5beta))- |
| phosphine oxide, ((1s,2s,5r)-5-methyl-2-(1-methylethyl)cyclohexyl)diphenyl- |
| (((1s,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl)-phenylphosphoryl)benzene |
| unii-h9lqp293gk |
| phosphine oxide, (5-methyl-2-(1-methylethyl)cyclohexyl)diphenyl-, (1s-(1.alpha.,2.alpha.,5.beta.))- |
| CS-0020060 |
| HY-100712 |
| Class | Description |
|---|---|
| monoterpenoid | Any terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| arylsulfatase A | Homo sapiens (human) | Potency | 0.2685 | AID720538 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 8.9125 | AID504332 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 0.0047 | AID488953 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.4368 | AID588795 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | IC50 | 0.2650 | AID476474; AID692804 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X | |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60ISSN: 1873-3913 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 ISSN: 1946-6242 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 ISSN: 1946-6242 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 ISSN: 0021-9258 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 ISSN: 1946-6242 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 ISSN: 1932-6203 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 ISSN: 1932-6203 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 ISSN: 1932-6203 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 ISSN: 1552-454X | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2022 | Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1 ISSN: 1475-6374 | |
| AID724063 | Lipophilicity, log D of compound at pH 7.4 | 2013 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3 ISSN: 1464-3405 | Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5. |
| AID692806 | Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method | 2012 | ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9 ISSN: 1948-5875 | Symmetric kv1.5 blockers discovered by focused screening. |
| AID692804 | Inhibition of human Kv1.5 ion channel after 3 mins by high-throughput planar patch clamp assay | 2012 | ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9 ISSN: 1948-5875 | Symmetric kv1.5 blockers discovered by focused screening. |
| AID476474 | Inhibition of human Kv1.5 channel expressed in CHO cells by whole cell patch clamp assay | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8 ISSN: 1464-3405 | Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2-amino-1,2-diphenylethanol | 2012 | 2012 | 12.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Contact Dermatitis | 0 | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Dermatitis, Contact | 0 | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2019 | 2020 | 4.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 | |
| Itching | 0 | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Malaria, Falciparum | 0 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Plasmodium falciparum Malaria | 0 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Pruritus | 0 | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |